Finasteride

Finasteride

SCHEMBL5148287

CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C.CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SRD5A2

The experimentally established mechanism targets of Finasteride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SRD5A2 known ✓ P31213 9/20 1.00
SRD5A1 P18405 16/20 1.00
LMNA P02545 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2C9 P11712 2/20 1.00
CYP2C19 P33261 2/20 1.00
ABCC4 O15439 1/20 1.00
ABCB11 O95342 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
CHRM1 P11229 1/20 1.00
HSD3B1 P14060 1/20 1.00
NFKB1 P19838 1/20 1.00
MAPK1 P28482 1/20 1.00
THPO P40225 1/20 1.00
BLM P54132 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Finasteride SCHEMBL1560981 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL11909 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL5509 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL13575812 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL21969512 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL3982016 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL22032590 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL22564355 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL21969513 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9
Finasteride SCHEMBL6448111 1.00 SRD5A1 (1.00) SRD5A1SRD5A2LMNACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675838-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS Puretecch LYT, Inc. (US) 2020-07-08 EP disclosed
US-10568900-B1 Androgen effectors PAXTON PIERSON SUZANNE JANINE (US) 2020-02-25 US disclosed
CN-110448525-A A kind of external application Finasteride lipid nanometer preparation and preparation method thereof prevented hair loss with growth-promoting hair WUXI PAILIEBO BIOLOGICAL MEDICINE TECH CO LTD 2019-11-15 CN disclosed
WO-2019046491-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS ARIYA THERAPEUTICS, INC. (US) 2019-03-07 WO disclosed
US-10111895-B2 Androgen effectors Paxton-Pierson, Suzanne J. (US) 2018-10-30 US disclosed
US-20170151271-A1 Novel Androgen Effectors PAXTON-PIERSON SUZANNE JANINE (US) 2017-06-01 US disclosed
EP-3171859-A1 PHARMACEUTICAL COMPOSITION COMPRISING 5ALPHA-REDUCTASE INHIBITOR Chong Kun Dang Pharmaceutical Corp. (KR) 2017-05-31 EP disclosed
US-20160175436-A1 COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES VICUS THERAPEUTICS LLC (US) 2016-06-23 US disclosed
WO-2016013829-A1 PHARMACEUTICAL COMPOSITION COMPRISING 5ALPHA-REDUCTASE INHIBITOR CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2016-01-28 WO disclosed
EP-1868432-A2 METHODS FOR TREATING ANXIETY RELATED DISORDERS Hythiam, Inc. (US) 2007-12-26 EP disclosed
WO-2006110580-A2 METHODS FOR TREATING ANXIETY RELATED DISORDERS HYTHIAM, INC. (US) 2006-10-19 WO disclosed
US-6048869-A REDUCTASE INHIBITORS MERCK & CO., INC. (US) 2000-04-11 US disclosed
US-5574011-A LH-RH DERIVATIVES TIEN, PAUL S. 1996-11-12 US disclosed
US-5344651-A Steroid antisecretory agents for sebaceous glands of scalp, hair growth regulators, antiinflammatory agents and treatment of acne THE PROCTER & GAMBLE COMPANY (US) 1994-09-06 US disclosed